COMPASSIONATE SUD CARE:

TRAUMA-INFORMED, CULTURALLY RESPONSIVE, AND STIGMA-FREE PRACTICES FOR EQUITABLE HEALING

PRNworld

COMPASSIONATE SUD CARE:

TRAUMA-INFORMED, CULTURALLY RESPONSIVE, AND STIGMA-FREE PRACTICES FOR EQUITABLE HEALING

ANCC Accredited NCPD Hours: 1.5 hrs

Target Audience: RN/APRN

NEEDS ASSESSMENT

Substance use disorders and chronic pain disproportionately affect individuals with histories of trauma, discrimination, and unmet social needs. According to **SAMHSA (2023)**, over **60% of individuals with SUDs report adverse childhood experiences (ACEs)**, which are strongly linked to poorer health outcomes and treatment dropout. In addition, data from **Health Services Research (2023)** reveal that **Black and Hispanic individuals are up to 50% less likely** to access medication for opioid use disorder (MOUD) compared to White patients, reflecting systemic inequities in healthcare delivery.

Stigma remains a major barrier, discouraging individuals from seeking or adhering to care. Language that labels patients as "addicts" or frames treatment in punitive terms reduces trust and worsens health outcomes. Evidence shows that **person-first, recovery-oriented language** improves engagement by **25% (AJPH, 2020)**. Moreover, **a 2022 Journal of Substance Abuse Treatment study** found that trauma-informed care increased treatment retention by **30%** in patients with SUD and trauma histories.

Despite these findings, many healthcare providers remain undertrained in applying trauma-informed, stigma-free, and culturally competent care principles.

This results in missed opportunities for connection, perpetuates disparities, and contributes to suboptimal treatment outcomes. A coordinated shift in provider education and practice is urgently needed to bridge these gaps and uphold ethical standards in addiction care.

OBJECTIVES

By the end of this module, participants will be able to:

- Apply trauma-informed communication strategies that promote psychological safety and avoid re-traumatisation.
- Identify and implement stigma-reducing language and nonjudgmental practices in SUD and chronic pain care.
- Deliver culturally responsive care that respects diverse beliefs, traditions, and lived experiences.
- Recognise and comply with legal and ethical mandates related to non-discrimination, trauma-informed care, and equitable access to SUD treatment.

GOALS

This module aims to help providers offer care that is respectful, safe, and fair for all individuals with SUDs or chronic pain. It helps them better understand trauma, reduce stigma, and respond to patients' cultural needs. By doing so, providers can build trust, improve treatment success, and promote recovery for people who have often been overlooked or misunderstood in the healthcare system.

INTRODUCTION

Effective care for individuals with substance use disorders (SUDs) demands more than clinical expertise or pharmacologic intervention; it requires a compassionate, inclusive, and trauma-informed approach that recognises the full context of each patient's experience. Many individuals living with SUD and/or chronic pain have endured adverse life events, systemic discrimination, and healthcare-related stigma, all of which can erode trust and discourage engagement with treatment.

To address these complex challenges, healthcare professionals must move beyond symptom-focused models and embrace frameworks that prioritise safety, empathy, and equity. Trauma-informed, culturally responsive, and stigma-reducing care is not only ethically imperative but clinically essential. These principles foster stronger therapeutic alliances, empower patient voice and choice, and improve outcomes by acknowledging the lived realities that shape health behaviours and treatment engagement.

This module aims to equip clinicians with the skills and insights necessary to deliver care that affirms dignity, respects diversity, and minimises re-traumatisation. By adopting inclusive language, recognising the impact of social determinants, and tailoring interventions to reflect individual and cultural values, providers can create safer and more effective pathways to recovery, ultimately advancing equity, trust, and long-term healing in SUD management.

TRAUMA-INFORMED, STIGMA-REDUCING, AND CULTURALLY RESPONSIVE CARE FOR PATIENTS WITH SUD AND/OR CHRONIC PAIN

Substance Use Disorders (SUDs) and chronic pain are complex, frequently co-occurring conditions that are deeply influenced by personal trauma, social stigma, and cultural context. Many individuals affected by these conditions face systemic barriers to compassionate, equitable care, often leading to mistrust, undertreatment, and poor health outcomes. In response, healthcare systems are increasingly embracing **trauma-informed**, **stigma-reducing**, and **culturally responsive** approaches to care. These models prioritise safety, empathy, and respect, aiming to rebuild trust, improve communication, and promote healing. This framework is not only ethical, it is evidence-based, patient-centred, and essential to improving outcomes in populations most at risk.

TRAUMA-INFORMED CARE (TIC): PRINCIPLES, STRATEGIES, AND CLINICAL APPLICATION

Trauma-Informed Care (TIC) is an evidence-based, person-centred approach that recognises the widespread prevalence of trauma, particularly among individuals with substance use disorders (SUDs) and/or chronic pain, and its profound impact on health behaviours, neurobiology, and treatment engagement. TIC shifts the clinical perspective from "What's wrong with you?" to "What happened to you?", emphasising empathy, safety, and collaboration.

CORE PRINCIPLES OF TIC

Outlined by **SAMHSA**, the six key principles of trauma-informed care serve as a foundation for clinical interaction:

1. **Safety**
   - Prioritise physical and emotional safety in all care settings.
   - Provide calm, predictable environments and protect patient privacy.

2. **Trustworthiness and Transparency**

- Build trust through clear, honest, and respectful communication.
- Be consistent in follow-through and explain care processes thoroughly.

3. **Peer Support**
   - Incorporate peer recovery specialists or those with lived experience to foster trust and shared understanding.
   - Promote participation in peer-led groups and mentorship.

4. **Collaboration and Mutuality**
   - Engage patients as equal partners in care planning.
   - Value interdisciplinary teamwork and flatten hierarchical relationships.

5. **Empowerment, Voice, and Choice**
   - Offer choices, encourage shared decision-making, and emphasise patient autonomy.
   - Focus on patient strengths and skill-building.

6. **Cultural, Historical, and Gender Considerations**
   - Recognise the impact of systemic oppression, racism, and historical trauma.
   - Adapt care to be culturally sensitive and inclusive.

TRAUMA-INFORMED STRATEGIES IN PRACTICE

1. Screen for Trauma Gently

- Use validated tools like the **Adverse Childhood Experiences (ACEs) Questionnaire** or **PC-PTSD-5**.
- Phrase sensitively: *"Have there been experiences in your life that felt overwhelming or unsafe?"*

2. Create a Safe Environment

- Ensure **private, calm, and respectful** settings.
- Train staff to recognise trauma responses (e.g., hypervigilance, dissociation) and respond nonjudgmentally.

3. Use Trauma-Informed Pain Management

- Avoid abrupt opioid discontinuation; use **gradual tapering** protocols as per CDC guidelines (Pain Medicine, 2021).
- Integrate non-opioid therapies like **CBT, mindfulness, physical therapy**, and **motivational interviewing**.

4. Apply TIC in Medication-Assisted Treatment (MAT)

- Monitor for trauma-related triggers using tools like the **Clinical Opiate Withdrawal Scale (COWS)**.

- Offer **trauma-focused psychosocial support** (e.g., EMDR, TF-CBT) alongside MAT to reduce relapse risk.

EVIDENCE HIGHLIGHT:
A 2022 Journal of Substance Abuse Treatment study found that implementing TIC improved treatment retention by 30% among SUD patients with trauma histories. Additionally, ACEs are present in over 60% of SUD patients (JAMA Psychiatry, 2020), indicating the critical need for trauma-informed approaches.

CLINICAL IMPLICATIONS
- Improved Trust: Validating trauma experiences fosters stronger therapeutic alliances.
- Better Adherence: TIC reduces treatment dropout and improves engagement in MAT and pain care.
- Safety and Equity: Promotes psychological safety and reduces the risk of re-traumatisation.

STIGMA-REDUCING CARE: PRINCIPLES, STRATEGIES, AND CLINICAL IMPLICATIONS

Stigma manifested through judgmental language, implicit bias, and structural barriers remains a major obstacle to effective care for individuals with **substance use disorders (SUDs)** and **chronic pain**. It fosters shame, discourages help-seeking, and diminishes treatment adherence. Stigma-reducing care requires intentional language choices, provider education, patient-centred communication, and systemic advocacy to promote equitable, compassionate care.

CORE PRINCIPLES

1. **Language Shapes Perception**
   - **Use Person-First Language**: Replace stigmatizing labels (e.g., "addict," "junkie") with respectful alternatives (e.g., "person with OUD," "patient managing SUD").

   - **Avoid Judgmental Terms**: Replace "clean/dirty" drug screen descriptors with clinical terms like "positive/negative."

- **Promote Recovery-Oriented Language**: Refer to treatment success as "remission" or "recovery," not "abstinence."



2. **Educate Clinicians and Staff**
   - Train all care team members on **addiction as a chronic disease**, not a moral failing.
   - Utilise tools such as **SAMHSA's stigma reduction toolkit** and **implicit bias training** programs.
   - Include education on chronic pain as a **biopsychosocial condition**, not a psychological weakness.

3. **Normalise Evidence-Based Treatment**
   - Present **Medication for Opioid Use Disorder (MOUD)** as standard, effective care similar to insulin for diabetes.
   - Co-prescribe **naloxone** as a routine safety measure, without judgment.



4. **Use Patient-Centred Communication**
   - Practice **motivational interviewing (MI)** to align treatment with the patient's goals and values.

Example: "What's important to you in managing your pain right now?"

   - Avoid punitive responses to relapse; treat it as a clinical signal to adjust care.

5. **Empathy and Compassion in Clinical Practice**
   - Use **active listening** and validate the patient's lived experience.
   - Be aware of **non-verbal cues** (e.g., facial expressions, body language) that may convey judgment.
   - Acknowledge barriers patients face, such as cravings, fear of withdrawal, and societal judgment.

6. **Advocate for Systemic Change**
    - Address institutional and insurance policies that limit access to **MAT**, **harm reduction**, or integrated pain care.
    - Support public awareness campaigns that normalise recovery and reduce stigma.
    - Endorse harm reduction practices (e.g., syringe exchange programs), shown to increase treatment access and reduce stigma.

CULTURALLY RESPONSIVE CARE: PRINCIPLES, STRATEGIES, AND CLINICAL IMPLICATIONS

Culturally responsive care acknowledges and integrates the cultural, linguistic, historical, and social identities of patients into healthcare delivery. This approach is especially vital for individuals with **substance use disorders (SUDs)** and **chronic pain**, who often encounter compounded disparities due to race, ethnicity, language, immigration status, and socioeconomic conditions.

CLINICAL IMPLICATIONS

- Improved Communication: Respectful, nonjudgmental language encourages open disclosure of substance use and pain symptoms.
- Enhanced Outcomes: Stigma-reducing care is linked to lower relapse rates, better treatment adherence, and improved chronic pain outcomes.
- Trust and Engagement: Patients are more likely to return and participate in their care when they feel respected and understood.

EVIDENCE

According to Health Services Research (2023), Black and Hispanic patients are significantly less likely to access Medication for Opioid Use Disorder (MOUD) compared to their White counterparts, reflecting structural inequities in care delivery.





Evidence:
A 2021 JAMA Network Open study found stigma-reduction initiatives increased treatment uptake for SUD by 20%.

CORE PRINCIPLES

1. **Self-Awareness and Cultural Humility**
    - **Critically Examine Biases**: Recognise and challenge personal assumptions, stereotypes, and cultural blind spots.
    - **Cultural Humility**:

Commit to lifelong learning. Acknowledge that no provider can be fully competent in another's culture but can remain open, curious, and respectful.

- **Power Dynamics**: Recognise how provider authority, combined with race, gender, or socioeconomic differences, can hinder open dialogue.

2. **Knowledge of Cultural and Historical Context**
   - **Cultural Beliefs & Health Narratives**: Understand how cultural norms shape interpretations of pain, addiction, healing, and treatment expectations.
   - **Historical Trauma**: Acknowledge the enduring impact of systemic oppression (e.g., colonisation, forced sterilisation, the War on Drugs) on trust in healthcare systems.
   - **Intersectionality**: Consider how multiple identities (e.g., LGBTQ+, immigrant status, poverty) influence health experiences and outcomes.

3. **Effective Communication and Relationship Building**
   - **Open-Ended Dialogue**: Invite patients to describe their health experiences in their terms.

Example: "How do you view your symptoms or condition?"

   - **Professional Interpretation Services**: Use trained medical interpreters, not family, for non-English-speaking patients. Provide translated written materials (e.g., consent forms, naloxone instructions).
   - **Cultural Nonverbal Norms**: Respect differences in eye contact, touch, tone, and body language.
   - **Collaborative Treatment Planning**: Negotiate care plans that reflect cultural values, family dynamics, and spiritual or traditional healing practices.

4. **Tailored Interventions**
   - **Culturally Adapted Models**: Modify evidence-based practices (e.g., CBT, MAT) to incorporate culturally relevant content.

Example: For Native American patients, include ceremonial practices (e.g., smudging, talking circles) within MAT programs. For Hispanic/Latino patients, include family members in treatment decisions, aligning with collectivist values (*JSAT, 2022).*

   - **Address Social Determinants of Health**: Screen for housing, food security, transportation, and discrimination using

tools like **PRAPARE**. Connect patients to social resources.

- **Workforce Representation**: Employ peer navigators or community health workers who share cultural backgrounds with patients.

5. **Community Engagement and Advocacy**
   - **Local Partnerships**: Collaborate with trusted institutions such as **faith-based groups**, **tribal councils**, or **immigrant support centres**.
   - **Advocate for Access Equity**: Push for expanded MAT programs and pain management services in underserved communities, including rural areas and BIPOC-majority neighbourhoods.

CLINICAL IMPLICATIONS

- Trust and Engagement: Cultural alignment fosters rapport, essential for sustained care, particularly for the 2.7 million Americans living with OUD (SAMHSA, 2020).
- Improved Outcomes: Culturally responsive care has been shown to reduce disparities in access to MAT and pain management, improving both clinical and patient-reported outcomes.
- Patient Empowerment: Valuing patients lived experiences and cultural wisdom promotes shared decision-making and treatment adherence.

Evidence:
A 2023 Addiction study found that culturally tailored interventions improved MAT retention by 35% among racial/ethnic minority groups.

IMPLEMENTATION BEST PRACTICES

1. **Integrated Approach**:
   - Combine TIC, stigma reduction, and cultural responsiveness in all patient interactions.
   - Example: Use MI to explore trauma triggers in a culturally sensitive manner, avoiding stigmatising language.

2. **Staff Training**:
   - Mandate annual training on TIC, stigma, and cultural competence, using SAMHSA or CDC resources.
   - Include role-playing to practice empathetic communication (*Journal of General Internal Medicine*, 2021).

3. **Screening and Monitoring**:
    - Use validated tools (e.g., SBIRT, ORT) to identify SUD/pain risks, adapting questions for cultural relevance.
    - Monitor treatment adherence with UDS and patient-reported outcomes, ensuring non-punitive responses to non-compliance.

4. **Patient Empowerment**:
    - Involve patients in treatment planning (e.g., shared decision-making for MAT or pain therapies).
    - Provide naloxone education and harm reduction resources to empower safety (*CDC, 2023*).

5. **Systemic Change**:
    - Advocate for policies expanding MAT access (e.g., MATE Act, 2023) and reducing barriers in underserved areas.
    - Use Prescription Drug Monitoring Programs (PDMPs) equitably to prevent misuse without profiling (*Health Affairs*, 2020).

Trauma-informed, stigma-reducing, and culturally responsive care improves trust, communication, and outcomes for patients with SUDs and/or chronic pain. By screening for trauma, using person-first language, and tailoring interventions to cultural identities, providers can address barriers and enhance engagement. Integrating these principles with evidence-based tools (e.g., SBIRT, MAT, naloxone) and systemic advocacy ensures equitable care for vulnerable populations, aligning with the MATE Act's goal of expanding access to SUD treatment.

NAVIGATING ETHICAL AND LEGAL COMPLEXITIES IN CONTROLLED SUBSTANCE PRESCRIBING

Prescribing controlled substances such as opioids, benzodiazepines, stimulants, buprenorphine, and methadone demands a nuanced understanding of both ethical responsibilities and legal mandates. In the wake of the ongoing opioid crisis and heightened scrutiny of prescribing practices, healthcare providers must balance the imperative to relieve suffering with the duty to prevent misuse, diversion, and harm. This requires meticulous adherence to federal and state regulations, comprehensive documentation, and a transparent informed consent process. Whether managing chronic pain or treating Opioid Use Disorder (OUD), clinicians must ensure that care is evidence-based, patient-centred, and legally sound. This guide synthesises key considerations and best practices from 2020 to 2025 to support safe, compliant, and ethical prescribing in today's complex clinical landscape.

1. Ethical Considerations in Controlled Substance Prescribing

Prescribing controlled substances involves ethical complexities that require clinicians to balance individual patient care with broader public health responsibilities. Ethical prescribing aims to ensure access to effective pain management and substance use disorder (SUD) treatment while minimising the risk of misuse, diversion, and harm.

Core Ethical Principles

- **Beneficence**
  Prescribers must act in the patient's best interest by offering effective, evidence-based treatments. For example, Medication-Assisted Treatment (MAT) for Opioid Use Disorder (OUD) has been shown to reduce illicit opioid use by up to 50% (JAMA Psychiatry, 2020).
- **Non-Maleficence**
  This principle requires clinicians to minimise harm by avoiding overprescribing and preventing misuse, diversion, and overdose. The ethical stakes are high, with over 70,000 opioid-related deaths reported in 2019 (CDC, 2023).
- **Autonomy**
  Ethical practice includes respecting patient autonomy through shared decision-making and comprehensive informed consent, especially when prescribing medications with high abuse potential.
- **Justice**
  Equity in care is essential. Disparities in access persist, with Black and Hispanic patients having 50% lower access to MAT compared to White patients (Health Services Research, 2023). Ethical practice must address systemic barriers to ensure fair treatment for all.
- **Professional Responsibility**
  Clinicians have an ethical duty to maintain competence, update their knowledge of evolving guidelines, and reflect on their own biases and prescribing patterns.
- **Public Health**
  Prescribing decisions carry societal consequences. Providers must consider the broader implications of their practices on community health and opioid-related morbidity and mortality.

Key Ethical Challenges

- **Balancing Access and Safety**
  While only 10–20% of the 2.7 million individuals with OUD receive MAT (SAMHSA, 2022), diversion remains a concern; buprenorphine diversion rates range from 5–10%. Clinicians must navigate this tension between expanding access and maintaining safety.
- **Stigma in Care**

Stigmatising attitudes toward patients with SUD can result in inadequate treatment. Shifting to person-first language has been shown to improve patient engagement by 25% (American Journal of Public Health, 2020).

- **Opioid Tapering Dilemmas**
  Inappropriate or forced opioid tapers can be harmful, increasing risks of unmanaged pain and relapse. One study found a 59.9% relapse rate among patients tapered off opioids without adequate support (Drug and Alcohol Dependence, 2021).
- **Telemedicine Expansion**
  The temporary expansion of telemedicine access for MAT through 2025 (DEA, 2024) introduces ethical concerns about monitoring efficacy, patient privacy, and continuity of care in virtual settings.

Ethical Strategies and Best Practices

- **Utilise Risk Assessment Tools**
  Employ validated tools such as the *Opioid Risk Tool (ORT)* and *Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R)* to guide safe, individualised prescribing decisions.
- **Implement Trauma-Informed Care**
  Integrating trauma-informed approaches helps clinicians build trust and recognise patient vulnerabilities, improving adherence and outcomes (Journal of Substance Abuse Treatment, 2022).
- **Advance Health Equity**
  Advocate for and implement policies that reduce barriers to care. Support efforts aligned with initiatives like the *Medication Access and Treatment Expansion (MATE) Act* to increase provider education and treatment capacity (SAMHSA, 2023).

2. Documentation in Controlled Substance Prescribing

"If it isn't documented, it didn't happen."

This foundational principle is especially critical when prescribing controlled substances, where regulatory scrutiny, patient safety, and clinical accountability intersect. Thorough documentation not only ensures legal compliance but also strengthens clinical decision-making and minimises liability risk.

Purpose of Documentation

- Ensure legal and regulatory compliance with federal and state mandates
- Support clinical reasoning and continuity of care
- Protect the provider from legal claims and professional liability
- Promote transparency and patient safety



Essential Components of Documentation

1. Comprehensive Patient Evaluation

- **Medical History**

  Include history of present illness, past medical/surgical history, psychiatric history, family history of substance use disorder (SUD), and all current medications, including over-the-counter and illicit substances.

- **Pain or SUD Assessment**
  - For pain:

    Document location, severity (using validated scales), duration, aggravate - ing/relieving factors, and impact on daily functioning.
  - For SUD:

    Record type of substance, durat - ion/frequency of use, previous treatments, and impact on life.

- **Psychosocial History**

  Document mental health conditions, trauma history, social support, employment status, and risk factors for misuse or diversion.

- **Physical Examination**

  Record findings that support the diagnosis and rationale for controlled substance use.

- **Functional Goals**

  Include realistic, patient-centred goals such as improved mobility, ability to work, or better sleep.

2. Treatment Plan

- **Diagnosis and Therapeutic Justification**

  Document the diagnosis and rationale for using controlled substances.

- **Specific Treatment Objectives**

  Define measurable outcomes such as redu ction in pain scores, abstinence from illicit substances, or improved function.

- **Multimodal Approach**

  Document integration of non-opioid medications, non-pharmacologic therapies (e.g., CBT, PT, acupuncture), and referrals to specialists.

- **Medication Details**

  Specify:
  - Drug name, strength, and dosage form
  - Quantity prescribed and number of refills
  - Clear instructions for use
  - Any deviation from standard protocols, with rationale

3. Risk Assessment and Mitigation

- **Validated Risk Tools**

Record scores from tools such as:

- *Opioid Risk Tool (ORT)*
- *Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R)*

- **Aberrant Behaviours**

  Document any red flags (e.g., early refill requests, pharmacy shopping) and clinical response.
- **Naloxone Co-prescribing**

  Especially for high-risk patients, document education and co-prescription of naloxone (CDC, 2023).
- **Periodic Review**

  Include treatment re-evaluation, effectiveness of the therapy, adherence to agreements, and any modifications to the plan.

4. Informed Consent and Treatment Agreements

- **Informed Consent**

  Document discussions on:
  - Risks (e.g., respiratory depression, addiction, overdose)
  - Benefits and alternatives
  - Patient questions and responses
- **Treatment Agreement**

  Include signed agreements outlining:
  - Urine Drug Screens (UDS)
  - Prescription Drug Monitoring Program (PDMP) checks
  - Single prescriber/pharmacy policy
  - Termination criteria for therapy

5. Monitoring and Follow-Up

- **UDS and PDMP Logs**

  Record results of drug screens and PDMP checks; note frequency (e.g., weekly during initiation, monthly after stabilisation).
- **Adverse Effects**

  Document side effects (e.g., methadone-induced QTc prolongation) and how they were managed.
- **Consultations and Referrals**

  Note all speciality referrals and communication with consulting providers.
- **Patient Education**

  Record topics discussed, including medication safety, storage, disposal, overdose prevention, and adherence expectations.

6. Regulatory Compliance

- **DEA and State Regulations**
  - Document completion of MATE Act 8-hour training (DEA, 2023)
  - Ensure prescriptions comply with Schedule-specific rules (e.g., Schedule II no refills; Schedule III–V refill limits)
- **Telemedicine Compliance**
  - Note platform used, patient location, and legal compliance with remote prescribing laws (especially relevant through 2025 for MAT per DEA guidelines).

3. Informed Consent for Controlled Substance Prescribing

Informed consent is a dialogue, not a checkbox. It empowers patients to make educated decisions, safeguards providers, and fulfils ethical and legal obligations.

Purpose

Informed consent ensures that patients understand the **risks**, **benefits**, and **alternatives** to treatment with controlled substances. It is essential for respecting **patient autonomy**, meeting **legal standards**, and promoting **safe, ethical care**.

Components of the Informed Consent Process

Diagnosis and Purpose

- Explain the condition requiring controlled substances (e.g., chronic pain, opioid use disorder).
- Clarify the treatment's intended outcome: pain control, functional improvement, or opioid dependence stabilisation.

Risks

Discuss general and medication-specific risks, including:

- **Physical Dependence & Tolerance**
- **Addiction** and **Diversion**
- **Overdose and Death** (especially when combined with CNS depressants like alcohol or benzodiazepines)
- **Side Effects**
  - Buprenorphine: Precipitated withdrawal, constipation (10–20%)
  - Methadone: QTc prolongation, sedation, respiratory depression (especially in the first 2 weeks)
  - Long-term opioids: Hyperalgesia, cognitive impairment, endocrine effects
- **Special Populations**:
  Teratogenic risks, risks with driving, and effects in older adults

Benefits

- Reduced pain intensity or cravings
- Improved function and quality of life
- Reduced illicit opioid use (MAT reduces illicit use by up to 50%, *JAMA Psychiatry*, 2020)

Alternatives

- Non-opioid pharmacologic options (e.g., NSAIDs, anticonvulsants)
- Behavioural therapies (CBT, mindfulness, physical therapy)
- MAT options: Buprenorphine, methadone, naltrexone
- Abstinence-based or residential programs
- Risk of declining treatment or attempting non-pharmacologic care alon

Patient Responsibilities

Patients must agree to:

- Use the medication **exactly as prescribed**
- Avoid sharing or selling medication (diversion)
- Use **a single prescriber and pharmacy**
- **Safely store** and **properly dispose** of medications
- Avoid alcohol and unapproved CNS depressants
- Adhere to monitoring:
  - Urine drug screens (UDS)
  - Prescription Drug Monitoring Program (PDMP) checks
  - Pill counts
  - Regular follow-ups
- Disclose any other medications or illicit substances
- Understand that **aberrant behaviours** (e.g., early refills, lost prescriptions) may result in tapering or discontinuation
- Female patients: Must discuss contraception and risks during pregnancy

Treatment Agreement

- A written and signed document outlining expectations, responsibilities, monitoring requirements, and consequences of non-compliance
- Shown to increase adherence by **20%** (*Journal of General Internal Medicine*, 2022)

Patient Understanding

- Use **plain language** and offer **translated materials** when necessary
- Engage the patient in **shared decision-making**
- Use the **teach-back method** to confirm understanding
- Provide an opportunity for all questions to be asked and answered clearly

Documentation

- Use a **standardized informed consent form** (paper or EHR-integrated)
- Record:
  - Topics discussed (risks, benefits, alternatives)
  - Patient questions and responses
  - Patient agreement to monitoring and responsibilities
  - Signed treatment agreement or consent form
- Review and update at:
  - Treatment initiation
  - Annually
  - Upon significant changes (e.g., tapering, change in medication)

4. Federal and State Regulatory Compliance in Controlled Substance Prescribing

Adherence to federal and state regulations is not optional—it's a legal, ethical, and professional mandate.

I. Federal Regulations

Controlled Substances Act (CSA)

- **Drug Scheduling:**
  Categorises substances into Schedules I–V based on abuse potential and medical use.
- **Prescribing Rules Vary by Schedule:**
  - Schedule II:
    No refills; new prescription required
  - Schedules III–IV:
    Up to 5 refills within 6 months
  - Schedule V:
    Fewer restrictions, refills at prescriber's discretion

DEA Registration and Compliance

- **DEA Registration:**
  Required to prescribe Schedules II–V; must remain current.
- **MATE Act (2023):**
  Requires 8-hour substance use disorder training for initial DEA registration or renewal.
- **Recordkeeping:**
  Comply with DEA record retention, inventory, and storage guidelines.

Prescription Requirements

- Must include:
  - Patient and prescriber information
  - Drug name, strength, dosage, quantity
  - Instructions for use
  - DEA number
  - Signature and date

Electronic Prescribing for Controlled Substances (EPCS)

- Supported federally and **mandated in Medicare Part D** (SUPPORT Act).
- Must meet security standards (e.g., two-factor authentication).

Emergency Prescriptions (Schedule II)

- Permissible by phone in emergencies.
- Follow-up written/electronic prescription required within 7 days.

Ryan Haight Act (2008)

- Requires an **in-person evaluation** before prescribing controlled substances via telehealth unless an exception applies:
  - During a public health emergency
  - Via special DEA telemedicine registration
  - Under DEA's temporary audio-visual exceptions (through 2025)

Methadone Restrictions

- **For OUD:**

Must be dispensed only via **SAMHSA-certified OTPs**

- **Monitoring:**
  Baseline and follow-up ECG for QTc prolongation

Buprenorphine Prescribing

- **No longer requires an X-waiver** (per the MAT Act, 2022)
- **DEA-registered** clinicians may now prescribe for OUD; still subject to state-specific rules

Naloxone Co-Prescribing

- **Recommended by the CDC** for patients at high overdose risk (e.g., concurrent opioids and benzodiazepines)
- Associated with **25% reduction in overdose deaths** (CDC, 2023)

II. State-Specific Regulations

State laws often exceed federal requirements and vary widely; clinicians must know their local regulations.

Prescription Drug Monitoring Programs (PDMPs)

- **Mandatory Checks**:
  Most states require PDMP review before prescribing opioids and at regular intervals.
- **Documentation**:
  Record PDMP queries and related clinical decisions in the EHR.
- **Impact**:
  Use of PDMPs reduces prescription drug misuse by **15%** (Health Affairs, 2020)

Opioid Prescribing Limits

- Common rules include:
  - **Initial prescription duration limits** (e.g., 3–7 days for acute pain)
  - **Mandatory tapering schedules**
  - **Special rules for minors**

CME and Licensure Requirements

- Many states require **ongoing CME** in:
  - Pain management
  - Substance use disorders
  - Safe opioid prescribing

Treatment Agreements

- Some states mandate **opioid treatment contracts** for chronic use
- Must outline:
  - Patient expectations and responsibilities
  - Monitoring protocols
  - Consequences of non-adherence

Naloxone Mandates

- **Required in some states** for high-dose opioid users or when combined with benzodiazepines

Telemedicine Laws

- Govern:

- Need for **initial in-person evaluations**
- State licensure across borders
- Telehealth-specific documentation and consent

- Verify patient location and **comply with state-specific telehealth prescribing laws**

BEST PRACTICES FOR REGULATORY COMPLIANCE

Navigating ethical and legal complexities in controlled substance prescribing requires balancing patient care with compliance. Ethical principles guide safe, equitable prescribing, while robust documentation, informed consent, and adherence to federal (e.g., MATE Act, DEA telemedicine rules) and state regulations (e.g., PDMP mandates) ensure legal accountability. By integrating risk assessment, patient-centred communication, and systemic advocacy, providers can enhance outcomes for patients with OUD and chronic pain while mitigating misuse and diversion risks.

AREA	ACTION
DEA Compliance	Maintain registration, document MATE Act training
PDMP Use	Integrate checks into the workflow; audit use quarterly
Telemedicine	Use secure platforms; know DEA & state exceptions
Naloxone	Co-prescribe when indicated; document patient education
Documentation	Use standardised EHR templates and workflows
Training	Educate staff on federal/state rules, PDMP, and consent
Auditing	Conduct internal audits to identify and rectify noncompliance
Legal Review	Consult healthcare attorneys for complex regulations
State Updates	Regularly monitor your Board of Nursing, Medical Board, and Pharmacy Board websites for updates

KEY SUMMARY

Category	Requirement/Action	Key Notes
DEA Registration	Maintain active DEA license (Schedules II–V)	MATE Act requires 8-hour training on SUD for new/renewed registrations
Controlled Substances Act	Follow scheduling rules (e.g., Schedule II – no refills; III–IV – 5 refills/6 months)	Know prescribing limitations per schedule
Prescription Requirements	Include patient/prescriber info, drug details, DEA number, manual/electronic signature	Required for legal compliance
Electronic Prescribing (EPCS)	Use secure systems with two-factor authentication	Federally allowed; required for Medicare Part D (SUPPORT Act)
Emergency Schedule II Rx	Oral Rx allowed in emergency; follow-up written Rx within 7 days	For emergencies only
Ryan Haight Act	Requires an in-person visit before tele-Rx unless under exceptions	Exceptions include public health emergencies and DEA telehealth waivers
Methadone (OUD Treatment)	Prescribe only via SAMHSA-certified OTPs; monitor QTc	Cannot be prescribed in a general outpatient setting
Buprenorphine Prescribing	No X-waiver needed (MAT Act, 2022); must be DEA-registered	State rules may still apply
Naloxone Co-Prescribing	Follow CDC/state mandates for co-prescribing in high-risk situations	Shown to reduce overdose deaths by 25%
PDMP Utilization	Mandatory PDMP checks before prescribing and during treatment	Reduces misuse by 15% (Health Affairs, 2020); document in EHR
State Opioid Limits	Enforce state-mandated supply duration (e.g., 3–7 days for acute pain)	Varies by state
Continuing Education (CME)	Complete state-mandated CME on opioids, pain, and SUD	Often required for license renewal
Treatment Agreements	Use written contracts outlining patient responsibilities and monitoring	Some states mandate this for chronic opioid therapy
Telehealth Laws	Adhere to state-specific telehealth Rx laws, including licensure and in-person evaluations	Confirm patient location and applicable laws
Documentation	Standardise documentation in EHR: Rx details, PDMP use, consent, treatment plan	Essential for audits and legal protection
Internal Monitoring	Conduct audits, use EHR alerts (e.g., naloxone reminders), and staff training	Promotes compliance and safety
Legal & Ethical	Engage legal counsel and ethics committees when navigating complex prescribing scenarios	Especially for high-risk or unusual cases
Consultation		

STATE-SPECIFIC LAWS AND RULES

Arkansas
Prescription Drug Monitoring Program (PDMP) governed by Arkansas Code §§ 20-7-- 601 to 20-7-614, including reporting requirements and penalties for misuse. Schedule III-IV prescriptions are limited to 5 refills within 6 months. g requirements and penalties for misuse. Schedule III-IV prescriptions are limited to 5 refills within 6 months.
acep.orgleg.colorado.gov+6sos.arkansas.gov+6leg.colorado.gov+

Colorado
Mandatory PDMP query before second opioid prescription. Safe prescribing and dispensing guidelines are codified in the Colorado Revised Statutes § 12-30-114.
med.uvm.edu+3leg.colorado.gov+3law.justia.com+3

Nebraska
Revised Statutes §§ 71-2454 and 71-2455 establish the PDMP system and reporting obligations, including continuing education requirements.
health.ny.gov+15law.justia.com+15codes.findlaw.com+15

Michigan
2017 legislation (Public Acts, including PA 246) introduced prescribing limits, PDMP use, and diversion control measures.
https://www.netce.com/coursemedia/2613/extra-mi-regulations__MI.2613.pdf

New Mexico
Administrative Code Title 16, Chapter 10, Part 14 regulates pain management with controlled substances, including evaluation, dosing, and continuing education.
regulations.justia.com+15srca.nm.gov+15law.cornell.edu+15

New York
Regulations in NYCRR Title 10 Part 80 cover prescribing, dispensing, emergency orders, electronic prescriptions, and practitioner/pharmacist responsibilities.
law.cornell.edu+2health.ny.gov+2re

Washington
New opioid prescribing requirements promote safer practices, with guidelines on dose limits and acute prescribing (e.g., ⩽ 7-day supply).
doh.wa.gov+2wsma.org+2azdhs.gov

CONCLUSION

Delivering effective care for individuals with substance use disorders (SUDs) requires more than clinical knowledge; it demands empathy, cultural humility, and a trauma-informed lens. This module has emphasised the importance of creating therapeutic environments where patients feel safe, respected, and empowered, regardless of their background or life experience.

By integrating **trauma-informed commun - ication strategies**, clinicians can reduce re-traumatisation and foster trust, which is foundational to treatment adherence and long-term recovery. The intentional application of **stigma-reducing, patient-centred practices** helps dismantle harmful biases and ensures that individuals with SUDs are treated with the dignity and compassion they deserve.

Equally vital is the recognition of **cultural and social determinants of health** and the role they play in shaping access to care, health beliefs, and recovery outcomes. Clinicians who adopt **culturally responsive approaches** are better equipped to serve diverse populations and promote equity within addiction care.

Finally, awareness and adherence to **state-specific laws and professional mandates** such as anti-discrimination protections, parity requirements, and trauma-informed care policies reinforce the ethical, legal, and systemic responsibility to provide fair and inclusive treatment. Together, these competencies position healthcare professionals to lead with compassion, practice with integrity, and advocate for lasting change in the way we address substance use disorders across all communities.

REFERENCES

1. American Journal of Public Health (AJPH). (2020). *Effect of person-first language on engagement in addiction treatment*. https://ajph.aphapublications.org
2. Centres for Disease Control and Prevention (CDC). (2023). *Naloxone co-prescribing guidelines*. https://www.cdc.gov
3. Drake, C., & Link, B. G. (2020). Reframing

addiction: Stigma, policy, and the public. *Health Affairs*, 39(6), 952–958. https://doi.org/10.1377/hlthaff.2019.0091

4. Green, T. C., Bratberg, J., & Finnell, D. S. (2020). Opioid stigma and the limits of education. *American Journal of Public Health*, 110(3), 327–328. https://doi.org/10.2105/AJPH.2019.305558
5. Health Affairs. (2020). *PDMP use and opioid safety outcomes*. https://www.healthaffairs.org
6. Health Services Research. (2023). *Disparities in access to MOUD by race and ethnicity*. https://www.hsr.org
7. Journal of General Internal Medicine. (2022). *Impact of documentation practices in opioid prescribing*. https://link.springer.com
8. Journal of Substance Abuse Treatment. (2022). *Trauma-informed care improves retention in SUD treatment*. https://www.journalofsubstanceabusetreatment.com
9. Merrill, J. O., & Rhodes, L. A. (2021). Stigma in the treatment of addiction: Words matter. *Substance Abuse*, 42(4), 516–522. https://doi.org/10.1080/08897077.2020.1792110
10. National Institute on Drug Abuse (NIDA). (2023). *Substance use and adverse childhood experiences (ACEs)*. https://nida.nih.gov
11. National Institutes of Health (NIH). (2023). *Cultural respect in health care: A policy approach*. https://www.nih.gov
12. SAMHSA. (2020). *Adverse Childhood Experiences (ACEs) and substance use disorder*. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov
13. SAMHSA. (2023a). *Medication Access and Training Expansion (MATE) Act overview*. https://www.samhsa.gov
14. SAMHSA. (2023b). *Trauma and violence*. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/trauma-violence
15. SAMHSA. (2023c). *National guidelines for behavioral health crisis care*. https://www.samhsa.gov/crisis-guidelines
16. Substance Abuse and Mental Health Services Administration (SAMHSA). (2022). *TIP 57: Trauma-Informed Care in Behavioral Health Services*. https://store.samhsa.gov/product/TIP-57-Trauma-Informed-Care-in-Behavioral-Health-Services/SMA14-4816
17. U.S. Department of Health and Human Services (HHS). (2023). *Culturally and linguistically appropriate services (CLAS) standards*. https://thinkculturalhealth.hhs.gov

18. U.S. Department of Justice, DEA. (2024). *Telemedicine prescribing and MAT compliance*. https://www.deadiversion.usdoj.gov